See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin, a drug used for treating certain types of cancer, can potentially lead to allergic reactions or sensitivities. According to the drug's label information provided by the U.S. Food and Drug Administration (FDA), hypersensitivity reactions have been reported in patients receiving lurbinectedin [1]. These reactions can range from mild to severe and may include symptoms such as rash, hives, itching, difficulty breathing, tightness in the chest, swelling of the mouth, face, lips, or tongue, and unusual hoarseness [1].

It is important to note that not all patients will experience allergic reactions or sensitivities to lurbinectedin. However, healthcare providers should be aware of the potential for these reactions and monitor patients closely for any signs or symptoms [1]. If an allergic reaction occurs, it is crucial to seek immediate medical attention and to follow the healthcare provider's instructions for managing the reaction.

In summary, based on the available information from the FDA, lurbinectedin exposure can lead to allergic reactions or sensitivities, and healthcare providers should monitor patients closely for any signs or symptoms of these reactions.

Sources:
[1] U.S. Food and Drug Administration. (2020). Zepzelca (lurbinectedin) prescribing information. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214433s000lbl.pdf>
[2] DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/drugs/lurbinectedin>